APC 2059

Drug Profile

APC 2059

Latest Information Update: 02 Jul 2004

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer; Celera Genomics Group
  • Developer Celera Genomics Group
  • Class Anti-inflammatories; Dioxoles; Guanidines; Small molecules
  • Mechanism of Action Peptide hydrolase inhibitors; Tryptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Inflammatory bowel diseases; Psoriasis; Ulcerative colitis

Most Recent Events

  • 06 Jun 2004 Discontinued - Phase-I for Inflammatory bowel disease in USA (IV-injection)
  • 06 Jun 2004 Discontinued - Phase-II for Ulcerative colitis in USA (SC)
  • 30 Mar 2001 Clinical trials of APC 2059 in asthma postponed until 2002
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top